Literature DB >> 19917985

Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis.

K Yanagawa1, I Kawachi, Y Toyoshima, A Yokoseki, M Arakawa, A Hasegawa, T Ito, N Kojima, R Koike, K Tanaka, T Kosaka, C-F Tan, A Kakita, K Okamoto, M Tsujita, K Sakimura, H Takahashi, M Nishizawa.   

Abstract

BACKGROUND: Neuromyelitis optica (NMO) is a demyelinating syndrome characterized by myelitis and optic neuritis. Detection of anti-NMO immunoglobulin G antibody that binds to aquaporin-4 (AQP4) water channels allows the diagnosis of a limited form of NMO in the early stage with myelitis, but not optic neuritis. However, the detailed clinicopathologic features and long-term course of this limited form remain elusive.
METHODS: We investigated 8 patients with the limited form of NMO with myelitis in comparison with 9 patients with the definite form. RESULT: All patients with limited and definite form showed uniform relapsing-remitting courses, with no secondary progressive courses. Pathologic findings of biopsy specimens from the limited form were identical to those of autopsy from the definite form, demonstrating extremely active demyelination of plaques, extensive loss of AQP4 immunoreactivity in plaques, and diffuse infiltration by macrophages containing myelin basic proteins with thickened hyalinized blood vessels. Moreover, the definite form at the nadir of relapses displayed significantly higher amounts of the inflammatory cytokines interleukin (IL)-1beta and IL-6 in CSF than the limited form and multiple sclerosis.
CONCLUSION: This consistency of pathologic findings and uniformity of courses indicates that aquaporin 4-specific autoantibodies as the initiator of the neuromyelitis optica (NMO) lesion consistently play an important common role in the pathogenicity through the entire course, consisting of both limited and definite forms, and NMO continuously displays homogeneity of pathogenic effector immune mechanisms through terminal stages, whereas multiple sclerosis should be recognized as the heterogeneous 2-stage disease that could switch from inflammatory to degenerative phase. This report is a significant description comparing the pathologic and immunologic data of limited NMO with those of definite NMO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917985     DOI: 10.1212/WNL.0b013e3181c1deb9

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.

Authors:  S Siritho; I Nakashima; T Takahashi; K Fujihara; N Prayoonwiwat
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

2.  Neuromyelitis optica and pregnancy.

Authors:  Yára Dadalti Fragoso; Tarso Adoni; Denis Bernardi Bichuetti; Joseph Bruno Bidin Brooks; Maria Lucia Brito Ferreira; Enedina Maria Lobato Oliveira; Celso Luis Silva Oliveira; Sonia Beatriz Felix Ribeiro; Alex Eduardo Silva; Fabio Siquineli
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

3.  Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications.

Authors:  Romain Marignier; Pascale Giraudon; Sandra Vukusic; Christian Confavreux; Jérôme Honnorat
Journal:  Ther Adv Neurol Disord       Date:  2010-09       Impact factor: 6.570

4.  Immunopathological patterns from EAE and Theiler's virus infection: Is multiple sclerosis a homogenous 1-stage or heterogenous 2-stage disease?

Authors:  Nicholas E Martinez; Fumitaka Sato; Seiichi Omura; Alireza Minagar; J Steven Alexander; Ikuo Tsunoda
Journal:  Pathophysiology       Date:  2012-05-26

5.  Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Authors:  Norio Chihara; Toshimasa Aranami; Wakiro Sato; Yusei Miyazaki; Sachiko Miyake; Tomoko Okamoto; Masafumi Ogawa; Tatsushi Toda; Takashi Yamamura
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

Review 6.  AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

7.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

8.  Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.

Authors:  Hua Zhang; A S Verkman
Journal:  J Autoimmun       Date:  2014-03-31       Impact factor: 7.094

9.  Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.

Authors:  Matthew M Nour; Ichiro Nakashima; Ester Coutinho; Mark Woodhall; Filipa Sousa; Jon Revis; Yoshiki Takai; Jithin George; Joanna Kitley; Maria Ernestina Santos; Joseph M Nour; Fan Cheng; Hiroshi Kuroda; Tatsuro Misu; Ana Martins-da-Silva; Gabriele C DeLuca; Angela Vincent; Jacqueline Palace; Patrick Waters; Kazuo Fujihara; Maria Isabel Leite
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

10.  Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.

Authors:  Takuya Matsushita; Takahisa Tateishi; Noriko Isobe; Tomomi Yonekawa; Ryo Yamasaki; Dai Matsuse; Hiroyuki Murai; Jun-Ichi Kira
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.